




# AHCJ Vaccine Research Panel

**Aparna Deora**

*Medicinal Sciences Vaccine Category Lead at  
Pfizer*

March 10, 2023




# mRNA Vaccines




Research began in 1970s, and grew in interest in 1990s



In 2018, Pfizer and BioNTech came together to explore an mRNA flu vaccine



# A Remarkable Journey of Developing Pfizer/BioNTech mRNA Vaccine




\* Authorized or Approved in 70 countries as of April 14, 2021

\*\* Goal: Up to approximately 2.5B doses by end of 2021 assuming continuous process improvements, expansion at current facilities and adding new suppliers and contract manufacturers; 6 doses per vial

VRBPAC (Vaccines and Related Biological Products Advisory Committee); FIH (First in Human); CMA (Conditional Marketing Authorization); EUA (Emergency Use Authorization)

# Lightspeed Paradigm for Vaccine and Treatment Development



## Parallel Testing

*Design and test multiple constructs simultaneously*




## Expert Dose Selection

*Optimization of dose for vaccines and therapeutics*



## Streamlined Governance

*Empowered Teams and Swift Decision-Making While Maintaining Quality and Safety*



## At-Risk Investment

*Large Commercial Manufacturing Scale-Up*



## Faster Regulatory Dialogue

*Simplified, Near Real-Time Interactions*

# Contact

## ***Pfizer Media Contacts***

- **Subscribe to Pfizer.com newsroom** → [Newsroom Subscription | Pfizer](#)
  - Hear directly from Pfizer with timely news. Select areas of interest, or elect to receive all our announcements, then let us know how you prefer we reach you.
  - **General email** → [PfizerMediaRelations@pfizer.com](mailto:PfizerMediaRelations@pfizer.com): For media inquires and/or pitching storytelling opportunities
  - **Media Relations phone number** → **+1 (212) 733-1226**: Leave a voice mail on Pfizer media relations mailbox
  - **Specific reporter questions around this presentation** can be directed to Keanna Ghazvini via email ([keanna.ghazvini@pfizer.com](mailto:keanna.ghazvini@pfizer.com)).
- [Newsroom Subscription | Pfizer](#)